U.S. stock futures rose on Thursday following Wednesday's advances as investors digest tariff pauses amid earnings reports.

Coherent reported quarterly earnings of 95 cents per share which beat the analyst consensus estimate of 69 cents per share. The company reported quarterly sales of $1.44 billion which beat the analyst ...

SAN JOSE, Calif. - Rani Therapeutics Holdings , Inc. (NASDAQ:RANI), a clinical-stage biotherapeutics company with a market capitalization of $48.3 million, today announced promising results from a ...

Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

Rani Therapeutics (RANI) announced new pharmacokinetic and pharmacodynamic data from a preclinical study evaluating the oral delivery of the ...

SAN FRANCISCO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- LiveRamp ® (NYSE: RAMP), the leading data collaboration platform, today announced its financial results for the fiscal 2025 third quarter ended ...

Share on Pinterest Ozempic (semaglutide) is a medication approved by the Food and Drug Administration (FDA) to treat type 2 diabetes. Because Ozempic has been shown to boost weight loss in people ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

Novo Nordisk reported that adults with obesity achieved significant weight loss using their semaglutide treatment, but their shares dipped following the announcement. In contrast, Viking Therapeutics' ...

1 Day RANI 6.49% DJIA 1.08% Russell 2K 1.70% Health Care/Life Sciences 0.00% ...